You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

 

Online download statistics by month:

Online download statistics by month: April 2020 to June 2025

AbstractFullPdf
Apr 2020276276163
May 202022022059
Jun 2020989831
Jul 2020696926
Aug 2020363615
Sep 2020767630
Oct 2020808023
Nov 2020585726
Dec 2020474710
Jan 2021878724
Feb 2021474711
Mar 2021727224
Apr 2021727210
May 2021757624
Jun 2021707017
Jul 2021383824
Aug 2021444420
Sep 2021434326
Oct 2021626238
Nov 2021464628
Dec 2021333311
Jan 2022566317
Feb 2022283116
Mar 2022414316
Apr 2022535612
May 2022697024
Jun 2022515317
Jul 2022454917
Aug 2022485117
Sep 2022444726
Oct 2022373717
Nov 2022505326
Dec 2022464617
Jan 2023333413
Feb 2023656520
Mar 2023687022
Apr 2023202014
May 2023323220
Jun 2023313110
Jul 2023191913
Aug 202314155
Sep 2023242410
Oct 2023303020
Nov 202327277
Dec 2023676719
Jan 2024323339
Feb 2024424219
Mar 2024616264
Apr 2024434330
May 2024515116
Jun 2024454530
Jul 2024484915
Aug 2024333314
Sep 2024464632
Oct 2024474719
Nov 2024868718
Dec 2024808040
Jan 2025525210
Feb 202543437
Mar 2025757727
Apr 2025646521
May 2025707131
Jun 2025535322
Total361836611489